Symbol="CLDX"
AssetType="Common Stock"
Name="Celldex Therapeutics Inc"
Description="Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey."
CIK="744218"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES"
Address="53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="1531454000"
EBITDA="-112963000"
PERatio="None"
PEGRatio="0"
BookValue="6.41"
DividendPerShare="0"
DividendYield="0"
EPS="-2.46"
RevenuePerShareTTM="0.067"
ProfitMargin="0"
OperatingMarginTTM="-36.75"
ReturnOnAssetsTTM="-0.193"
ReturnOnEquityTTM="-0.339"
RevenueTTM="3150000"
GrossProfitTTM="-79901000"
DilutedEPSTTM="-2.46"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="4.557"
AnalystTargetPrice="65.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="1935.11"
PriceToBookRatio="5.07"
EVToRevenue="1326.45"
EVToEBITDA="-16.28"
Beta="2.1"
num_52WeekHigh="48.4"
num_52WeekLow="27.01"
num_50DayMovingAverage="35.28"
num_200DayMovingAverage="37.75"
SharesOutstanding="47252500"
DividendDate="2019-02-11"
ExDividendDate="None"
symbol="CLDX"
open="28.11"
high="30.53"
low="27.52"
price="30.52"
volume="892462.00"
latest_trading_day="2023-08-09"
previous_close="32.41"
change="-1.89"
change_percent="-5.8315%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="64"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="TRUE"
Aroon_momentum="36"
Volume_recent_avg="558737"
Change_recent_avg="-0.05"
Delta_recent_avg="1.54"
Variance_recent_avg="0.77"
Change_ratio_recent_avg="-0.17"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="TRUE"
Aroon_momentum_positive="36"
Aroon_momentum_negative="64"
image_negative_thumbnail_id_1="134"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0042.jpeg"
image_negative_thumbnail_id_2="123"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0053.jpeg"
image_neutral_thumbnail_id_1="588"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0011.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="703"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_positive_thumbnail_id_2="662"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0046.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1193"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
